Literature DB >> 28455658

Hemodialysis is associated with higher serum FGF23 level when compared with peritoneal dialysis.

Shuhong Bi1, Yaoxian Liang2, Litao Cheng2, Yue Wang2, Tao Wang2, Qinfeng Han2, Aihua Zhang2.   

Abstract

BACKGROUND: Considering the growing relevance of fibroblast growth factor-23 (FGF23) and increased cardiovascular mortality in dialysis population, an analysis was performed to assess the influence of dialysis modality (peritoneal dialysis and hemodialysis) on level of FGF23.
METHODS: A cross-sectional study was performed in 80 continuous ambulatory peritoneal dialysis (CAPD) and 65 hemodialysis (HD) patients without residual renal function. Levels of calcium, phosphate, parathyroid hormone and FGF23 were measured, and their correlations were analyzed. Data on demographics, dialysis modality and FGF23 level were also analyzed.
RESULTS: A significant correlation was found between FGF23 and serum calcium, serum phosphate and dialysis vintage in dialysis patients. Level of FGF23 was significantly higher in hemodialysis patients than that in peritoneal dialysis population. Multivariable regression revealed that, compared to CAPD, hemodialysis was found to be a predictor for higher FGF23 level, which was independent of serum calcium and phosphate level (P < 0.05).
CONCLUSIONS: These findings demonstrate that FGF23 levels are significantly higher in hemodialysis patients than that in peritoneal dialysis patients. We demonstrate an important association between dialysis modality (HD vs CAPD) and higher FGF23, independent of classical determinants (serum calcium and phosphate level).

Entities:  

Keywords:  FGF23; Hemodialysis; Peritoneal dialysis

Mesh:

Substances:

Year:  2017        PMID: 28455658     DOI: 10.1007/s11255-017-1605-z

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  20 in total

Review 1.  Middle molecules and small-molecular-weight proteins in ESRD: properties and strategies for their removal.

Authors:  William R Clark; James F Winchester
Journal:  Adv Ren Replace Ther       Date:  2003-10

2.  FGF23 beyond mineral metabolism: a bridge to cardiovascular disease.

Authors:  Tobias E Larsson
Journal:  Clin J Am Soc Nephrol       Date:  2011-12       Impact factor: 8.237

Review 3.  Calculation of the protein equivalent of total nitrogen appearance from urea appearance. Which formulas should be used?

Authors:  J Bergström; O Heimbürger; B Lindholm
Journal:  Perit Dial Int       Date:  1998 Sep-Oct       Impact factor: 1.756

Review 4.  The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe?

Authors:  Tobias E Larsson
Journal:  Nephrol Dial Transplant       Date:  2010-02-02       Impact factor: 5.992

5.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

Authors:  Tamara Isakova; Huiliang Xie; Wei Yang; Dawei Xie; Amanda Hyre Anderson; Julia Scialla; Patricia Wahl; Orlando M Gutiérrez; Susan Steigerwalt; Jiang He; Stanley Schwartz; Joan Lo; Akinlolu Ojo; James Sondheimer; Chi-yuan Hsu; James Lash; Mary Leonard; John W Kusek; Harold I Feldman; Myles Wolf
Journal:  JAMA       Date:  2011-06-15       Impact factor: 56.272

6.  Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism.

Authors:  Takashi Shimada; Yuji Yamazaki; Motoo Takahashi; Hisashi Hasegawa; Itaru Urakawa; Takeshi Oshima; Kaori Ono; Makoto Kakitani; Kazuma Tomizuka; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Am J Physiol Renal Physiol       Date:  2005-07-05

7.  Fibroblast growth factor 23 in patients undergoing peritoneal dialysis.

Authors:  Tamara Isakova; Huiliang Xie; Allison Barchi-Chung; Gabriela Vargas; Nicole Sowden; Jessica Houston; Patricia Wahl; Andrew Lundquist; Michael Epstein; Kelsey Smith; Gabriel Contreras; Luis Ortega; Oliver Lenz; Patricia Briones; Phyllis Egbert; T Alp Ikizler; Harald Jueppner; Myles Wolf
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-08       Impact factor: 8.237

Review 8.  Survival of hemodialysis patients and uremic toxin removal.

Authors:  R Vanholder; R De Smet; G Glorieux; A Dhondt
Journal:  Artif Organs       Date:  2003-03       Impact factor: 3.094

9.  Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.

Authors:  Myles Wolf; Miklos Z Molnar; Ansel P Amaral; Maria E Czira; Anna Rudas; Akos Ujszaszi; Istvan Kiss; Laszlo Rosivall; Janos Kosa; Peter Lakatos; Csaba P Kovesdy; Istvan Mucsi
Journal:  J Am Soc Nephrol       Date:  2011-03-24       Impact factor: 10.121

10.  High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.

Authors:  Guillaume Jean; Jean-Claude Terrat; Thierry Vanel; Jean-Marc Hurot; Christie Lorriaux; Brice Mayor; Charles Chazot
Journal:  Nephrol Dial Transplant       Date:  2009-04-25       Impact factor: 5.992

View more
  2 in total

1.  Fibroblast growth factor-23 correlates with advanced disease conditions and predicts high risk of major adverse cardiac and cerebral events in end-stage renal disease patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  Li Xu; Xiaosong Hu; Wenli Chen
Journal:  J Nephrol       Date:  2018-11-21       Impact factor: 3.902

2.  Fibroblast growth factor 23 (FGF23) level is associated with ultrafiltration rate in patients on hemodialysis.

Authors:  Yoko Nishizawa; Yumi Hosoda; Ai Horimoto; Kiyotsugu Omae; Kyoko Ito; Chieko Higuchi; Hiroshi Sakura; Kosaku Nitta; Tetsuya Ogawa
Journal:  Heart Vessels       Date:  2020-09-30       Impact factor: 2.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.